Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense

Immunological Reviews

Volumn 274, Issue 1, 2016, Pages 33-58

  Ricklin, Daniel ^a,d   Reis, Edimara S ^a   Mastellos, Dimitrios C ^a,b   Gros, Piet ^c   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^c UTRECHT UNIVERSITY   (Netherlands)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

compstatin; convertase; immune evasion; inflammation; therapeutics

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; OPSONIN;

COMPLEMENT ACTIVATION; COMPLEMENT FIXATION; COMPLEMENT INHIBITION; HOST RESISTANCE; HUMAN; IMMUNE EVASION; IMMUNOREGULATION; INNATE IMMUNITY; OPSONIZATION; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; EVOLUTION; IMMUNOLOGY; IMMUNOPATHOLOGY; IMMUNOTHERAPY; TRENDS;

ANIMALS; BIOLOGICAL EVOLUTION; COMPLEMENT ACTIVATION; COMPLEMENT C3; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY, INNATE; IMMUNOTHERAPY;

EID: 84992449633     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12500     Document Type: Review

References (231)

1. Ricklin D, Lambris JD. Preformed mediators of defense—Gatekeepersenter the spotlight. Immunol Rev. 2016;274:5–8.
2. Chaplin H Jr. Review: The burgeoning history of the complement system 1888-2005. Immunohematology. 2005;21:85–93.
3. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: A key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–797.
4. Ricklin D, Reis ES, Lambris JD. Complement in disease: A defence system turning offensive. Nat Rev Nephrol. 2016;12:383–401.
5. Merle NS, Noe R, Halbwachs-Mecarelli L, Fremeaux-Bacchi V, Roumenina LT. Complement system Part II: Role in immunity. Front Immunol. 2015;6:257.
6. Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system Part I—Molecular mechanisms of activation and regulation. Front Immunol. 2015;6:262.
7. Harboe M, Garred P, Karlstrom E, Lindstad JK, Stahl GL, Mollnes TE. The down-stream effects of mannan-induced lectin complement pathway activation depend quantitatively on alternative pathway amplification. Mol Immunol. 2009;47:373–380.
8. Harboe M, Ulvund G, Vien L, Fung M, Mollnes TE. The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation. Clin Exp Immunol. 2004;138:439–446.
9. Nilsson B, Nilsson Ekdahl K. The tick-over theory revisited: Is C3 a contact-activated protein? Immunobiology. 2012;217:1106–1110.
10. Oikonomopoulou K, DeAngelis RA, Chen H, et al. Induction of complement C3a receptor responses by kallikrein-related peptidase 14. J Immunol. 2013;191:3858–3866.
11. Amara U, Flierl MA, Rittirsch D, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010;185:5628–5636.
12. Erdei A, Sándor Nm, Mácsik-Valent B, Lukácsi S, Kremlitzka M, Bajtay Z. The versatile functions of complement C3-derived ligands. Immunol Rev. 2016;274:127–140.
13. Hong S, Beja-Glasser VF, Nfonoyim BM, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712–716.
14. Stephan AH, Barres BA, Stevens B. The complement system: An unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012;35:369–389.
15. Coulthard LG, Woodruff TM. Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth. J Immunol. 2015;194:3542–3548.
16. Markiewski MM, Mastellos D, Tudoran R, et al. C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J Immunol. 2004;173:747–754.
17. Haynes T, Luz-Madrigal A, Reis ES, et al. Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration. Nat Commun. 2013;4:2312.
18. Tsonis PA, Lambris JD, Del Rio-Tsonis K. To regeneration…with complement. Adv Exp Med Biol. 2006;586:63–70.
19. DeAngelis RA, Markiewski MM, Lambris JD. Liver regeneration: A link to inflammation through complement. Adv Exp Med Biol. 2006;586:17–34.
20. Reca R, Mastellos D, Majka M, et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood. 2003;101:3784–3793.
21. Reca R, Wysoczynski M, Yan J, Lambris JD, Ratajczak MZ. The role of third complement component (C3) in homing of hematopoietic stem/progenitor cells into bone marrow. Adv Exp Med Biol. 2006;586:35–51.
22. Broders-Bondon F, Paul-Gilloteaux P, Gazquez E, et al. Control of the collective migration of enteric neural crest cells by the Complement anaphylatoxin C3a and N-cadherin. Dev Biol. 2016;414:85–99.
23. Carmona-Fontaine C, Theveneau E, Tzekou A, et al. Complement fragment C3a controls mutual cell attraction during collective cell migration. Dev Cell. 2011;21:1026–1037.
24. Ruan BH, Li X, Winkler AR, et al. Complement C3a, CpG oligos, and DNA/C3a complex stimulate IFN-alpha production in a receptor for advanced glycation end product-dependent manner. J Immunol. 2010;185:4213–4222.
25. Klos A, Wende E, Wareham KJ, Monk PN. International Union of Basic and Clinical Pharmacology. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. Pharmacol Rev. 2013;65:500–543.
26. Nordahl EA, Rydengard V, Nyberg P, et al. Activation of the complement system generates antibacterial peptides. Proc Natl Acad Sci USA. 2004;101:16879–16884.
27. Schmidt C, Lambris J, Ricklin D. Protection of host cells by complement regulators. Immunol Rev. 2016;274:152–171.
28. Ricklin D. Manipulating the mediator: Modulation of the alternative complement pathway C3 convertase in health, disease and therapy. Immunobiology. 2012;217:1057–1066.
29. Forneris F, Wu J, Xue X, et al. Regulators of complement activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J. 2016;35:1133–1149.
30. Blom AM, Kask L, Dahlback B. CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b. Mol Immunol. 2003;39:547–556.
31. Blom A, Martin M. Complement in removal of the dead – Balancing inflammation. Immunol Rev. 2016;274:218–232.
32. Hajishengallis G, Lambris JD. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol. 2010;31:154–163.
33. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol. 2007;179:2600–2608.
34. Blatt A, Pathan S, Ferreira V. Properdin: A tightly regulated critical inflammatory modulator. Immunol Rev. 2016;274:172–190.
35. Harboe M, Garred P, Lindstad JK, et al. The role of properdin in zymosan- and Escherichia coli-induced complement activation. J Immunol. 2012;189:2606–2613.
36. Roumenina L, Rayes J, Frimat M, Fremeaux-Bacchi V. Endothelial cells: Source, barrier and target of defensive mediators. Immunol Rev. 2016;274:307–329.
37. Pickering M, Medjeral-Thomas N. The complement factor H-related proteins. Immunol Rev. 2016;274:191–201.
38. Jozsi M, Tortajada A, Uzonyi B, Goicoechea de Jorge E, Rodriguez de Cordoba S. Factor H-related proteins determine complement-activating surfaces. Trends Immunol. 2015;36:374–384.
39. Daigo K, Inforzato A, Barajon I, et al. Pentraxins in the activation and regulation of the innate immunity. Immunol Rev. 2016;274:202–217.
40. Sunyer JO, Lambris JD. Evolution and diversity of the complement system of poikilothermic vertebrates. Immunol Rev. 1998;166:39–57.
41. Pinto MR, Melillo D, Giacomelli S, Sfyroera G, Lambris JD. Ancient origin of the complement system: Emerging invertebrate models. Adv Exp Med Biol. 2007;598:372–388.
42. Nonaka M. Evolution of the complement system. Subcell Biochem. 2014;80:31–43.
43. Zarkadis IK, Mastellos D, Lambris JD. Phylogenetic aspects of the complement system. Dev Comp Immunol. 2001;25:745–762.
44. Nonaka M, Kimura A. Genomic view of the evolution of the complement system. Immunogenetics. 2006;58:701–713.
45. Smith LC, Clow LA, Terwilliger DP. The ancestral complement system in sea urchins. Immunol Rev. 2001;180:16–34.
46. Clow LA, Raftos DA, Gross PS, Smith LC. The sea urchin complement homologue, SpC3, functions as an opsonin. J Exp Biol. 2004;207:2147–2155.
47. Marino R, Kimura Y, De Santis R, Lambris JD, Pinto MR. Complement in urochordates: Cloning and characterization of two C3-like genes in the ascidian Ciona intestinalis. Immunogenetics. 2002;53:1055–1064.
48. Pinto MR, Chinnici CM, Kimura Y, et al. CiC3-1a-mediated chemotaxis in the deuterostome invertebrate Ciona intestinalis (Urochordata). J Immunol. 2003;171:5521–5528.
49. Melillo D, Sfyroera G, De Santis R, et al. First identification of a chemotactic receptor in an invertebrate species: Structural and functional characterization of Ciona intestinalis C3a receptor. J Immunol. 2006;177:4132–4140.
50. Lambris JD, Pappas J, Mavroidis M, et al. The third component of Xenopus complement: cDNA cloning, structural and functional analysis, and evidence for an alternate C3 transcript. Eur J Immunol. 1995;25:572–578.
51. Mavroidis M, Sunyer JO, Lambris JD. Isolation, primary structure, and evolution of the third component of chicken complement and evidence for a new member of the alpha 2-macroglobulin family. J Immunol. 1995;154:2164–2174.
52. Sunyer JO, Zarkadis IK, Sahu A, Lambris JD. Multiple forms of complement C3 in trout that differ in binding to complement activators. Proc Natl Acad Sci USA. 1996;93:8546–8551.
53. Sunyer JO, Zarkadis I, Sarrias MR, Hansen JD, Lambris JD. Cloning, structure, and function of two rainbow trout Bf molecules. J Immunol. 1998;161:4106–4114.
54. Sunyer JO, Tort L, Lambris JD. Structural C3 diversity in fish: Characterization of five forms of C3 in the diploid fish Sparus aurata. J Immunol. 1997;158:2813–2821.
55. Forn-Cuni G, Reis ES, Dios S, et al. The evolution and appearance of C3 duplications in fish originate an exclusive teleost c3 gene form with anti-inflammatory activity. PLoS ONE. 2014;9:e99673.
56. Boshra H, Wang T, Hove-Madsen L, et al. Characterization of a C3a receptor in rainbow trout and Xenopus: The first identification of C3a receptors in nonmammalian species. J Immunol. 2005;175:2427–2437.
57. Blandin S, Levashina EA. Thioester-containing proteins and insect immunity. Mol Immunol. 2004;40:903–908.
58. Janssen BJ, Huizinga EG, Raaijmakers HC, et al. Structures of complement component C3 provide insights into the function and evolution of immunity. Nature. 2005;437:505–511.
59. Lagueux M, Perrodou E, Levashina EA, Capovilla M, Hoffmann JA. Constitutive expression of a complement-like protein in toll and JAK gain-of-function mutants of Drosophila. Proc Natl Acad Sci USA. 2000;97:11427–11432.
60. Levashina EA, Moita LF, Blandin S, Vriend G, Lagueux M, Kafatos FC. Conserved role of a complement-like protein in phagocytosis revealed by dsRNA knockout in cultured cells of the mosquito, Anopheles gambiae. Cell. 2001;104:709–718.
61. Szabo A, Cobo I, Omara S, McLachlan S, Keller R, Mayor R. The molecular basis of radial intercalation during tissue spreading in early development. Dev Cell. 2016;37:213–225.
62. Sahu A, Lambris JD. Structure and biology of complement protein C3, a connecting link between innate and acquired immunity. Immunol Rev. 2001;180:35–48.
63. de Bruijn MH, Fey GH. Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci USA. 1985;82:708–712.
64. Misumi Y, Oda K, Fujiwara T, Takami N, Tashiro K, Ikehara Y. Functional expression of furin demonstrating its intracellular localization and endoprotease activity for processing of proalbumin and complement pro-C3. J Biol Chem. 1991;266:16954–16959.
65. Hirani S, Lambris JD, Muller-Eberhard HJ. Structural analysis of the asparagine-linked oligosaccharides of human complement component C3. Biochem J. 1986;233:613–616.
66. Nilsson Ekdahl K, Nilsson B. Phosphorylation of plasma proteins with emphasis on complement component C3. Mol Immunol. 1999;36:233–239.
67. Ekdahl KN, Ronnblom L, Sturfelt G, Nilsson B. Increased phosphate content in complement component C3, fibrinogen, vitronectin, and other plasma proteins in systemic lupus erythematosus: Covariation with platelet activation and possible association with thrombosis. Arthritis Rheum. 1997;40:2178–2186.
68. Tack BF, Harrison RA, Janatova J, Thomas ML, Prahl JW. Evidence for presence of an internal thiolester bond in third component of human complement. Proc Natl Acad Sci USA. 1980;77:5764–5768.
69. Morgan BP, Gasque P. Extrahepatic complement biosynthesis: Where, when and why? Clin Exp Immunol. 1997;107:1–7.
70. Marsh JE, Zhou W, Sacks SH. Local tissue complement synthesis–fine tuning a blunt instrument. Arch Immunol Ther Exp (Warsz). 2001;49(Suppl 1):S41–46.
71. Kolev M, Le Friec G, Kemper C. Complement–tapping into new sites and effector systems. Nat Rev Immunol. 2014;14:811–820.
72. Farrar CA, Zhou W, Lin T, Sacks SH. Local extravascular pool of C3 is a determinant of postischemic acute renal failure. FASEB J. 2006;20:217–226.
73. Sundsmo JS. The leukocyte complement system. Fed Proc. 1982;41:3094–3098.
74. Liszewski MK, Kolev M, Le Friec G, et al. Intracellular complement activation sustains T cell homeostasis and mediates effector differentiation. Immunity. 2013;39:1143–1157.
75. Arbore G, West EE, Spolski R, et al. T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4(+) T cells. Science. 2016;352:aad1210.
76. Frimat M, Tabarin F, Dimitrov JD, et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood. 2013;122:282–292.
77. Yang K, Dinasarapu AR, Reis ES, et al. CMAP: Complement map database. Bioinformatics. 2013;29:1832–1833.
78. Alsenz J, Becherer JD, Nilsson B, Lambris JD. Structural and functional analysis of C3 using monoclonal antibodies. Curr Top Microbiol Immunol. 1990;153:235–248.
79. Becherer JD, Alsenz J, Esparza I, Hack CE, Lambris JD. Segment spanning residues 727-768 of the complement C3 sequence contains a neoantigenic site and accommodates the binding of CR1, factor H, and factor B. Biochemistry. 1992;31:1787–1794.
80. Lambris JD, Lao Z, Oglesby TJ, Atkinson JP, Hack CE, Becherer JD. Dissection of CR1, factor H, membrane cofactor protein, and factor B binding and functional sites in the third complement component. J Immunol. 1996;156:4821–4832.
81. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med. 1981;154:856–867.
82. Pangburn MK, Muller-Eberhard HJ. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J Exp Med. 1980;152:1102–1114.
83. Hack CE, Paardekooper J, Smeenk RJ, Abbink J, Eerenberg AJ, Nuijens JH. Disruption of the internal thioester bond in the third component of complement (C3) results in the exposure of neodeterminants also present on activation products of C3. An analysis with monoclonal antibodies. J Immunol. 1988;141:1602–1609.
84. Winters MS, Spellman DS, Lambris JD. Solvent accessibility of native and hydrolyzed human complement protein 3 analyzed by hydrogen/deuterium exchange and mass spectrometry. J Immunol. 2005;174:3469–3474.
85. Nishida N, Walz T, Springer TA. Structural transitions of complement component C3 and its activation products. Proc Natl Acad Sci USA. 2006;103:19737–19742.
86. 2O) revealed by quantitative cross-linking/mass spectrometry and modeling. Mol Cell Proteomics. 2016;15:2730–2743.
87. Li K, Gor J, Perkins SJ. Self-association and domain rearrangements between complement C3 and C3u provide insight into the activation mechanism of C3. Biochem J. 2010;431:63–72.
88. 2O)Bb). Mol Immunol. 2008;45:2370–2379.
89. 2O) and factor B in solution. J Biol Chem. 1988;263:1733–1738.
90. Forneris F, Ricklin D, Wu J, et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science. 2010;330:1816–1820.
91. Janssen BJ, Christodoulidou A, McCarthy A, Lambris JD, Gros P. Structure of C3b reveals conformational changes that underlie complement activity. Nature. 2006;444:213–216.
92. Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, Gros P. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol. 2009;10:728–733.
93. Rooijakkers SH, Wu J, Ruyken M, et al. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol. 2009;10:721–727.
94. Wiesmann C, Katschke KJ, Yin J, et al. Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature. 2006;444:217–220.
95. Katschke KJ Jr, Stawicki S, Yin J, et al. Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement. J Biol Chem. 2009;284:10473–10479.
96. Abdul Ajees A, Volanakis JE, Narayana SV. Retraction: The structure of complement C3b provides insights into complement activation and regulation. Nature. 2016;532:268.
97. Janssen BJ, Read RJ, Brunger AT, Gros P. Crystallography: Crystallographic evidence for deviating C3b structure. Nature. 2007;448:E1–2; discussion E2-3.
98. Ponnuraj K, Xu Y, Macon K, Moore D, Volanakis JE, Narayana SV. Structural analysis of engineered Bb fragment of complement factor B: Insights into the activation mechanism of the alternative pathway C3-convertase. Mol Cell. 2004;14:17–28.
99. Milder FJ, Gomes L, Schouten A, et al. Factor B structure provides insights into activation of the central protease of the complement system. Nat Struct Mol Biol. 2007;14:224–228.
100. Narayana SV, Carson M, el-Kabbani O, et al. Structure of human factor D. A complement system protein at 2.0 A resolution. J Mol Biol. 1994;235:695–708.
101. Hourcade DE, Mitchell LM, Oglesby TJ. Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding. J Immunol. 1999;162:2906–2911.
102. Janssen BJ, Gomes L, Koning RI, et al. Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex. EMBO J. 2009;28:2469–2478.
103. Ricklin D, Tzekou A, Garcia BL, et al. A molecular insight into complement evasion by the staphylococcal complement inhibitor protein family. J Immunol. 2009;183:2565–2574.
104. Rooijakkers SH, Ruyken M, Roos A, et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat Immunol. 2005;6:920–927.
105. 2+) proconvertase. J Immunol. 2009;183:7347–7351.
106. Laursen NS, Andersen KR, Braren I, Spillner E, Sottrup-Jensen L, Andersen GR. Substrate recognition by complement convertases revealed in the C5-cobra venom factor complex. EMBO J. 2011;30:606–616.
107. Roversi P, Johnson S, Caesar JJ, et al. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc Natl Acad Sci USA. 2011;108:12839–12844.
108. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: Pathophysiological mechanisms. J Immunol. 2013;190:3831–3838.
109. Verschoor A, Karsten C, Broadley S, Laumonnier Y, Köhl J. Old dogs—New tricks: Immunoregulatory properties of C3 and C5 cleavage fragments. Immunol Rev. 2016;274:112–126.
110. Kemper C, Kohl J. Novel roles for complement receptors in T cell regulation and beyond. Mol Immunol. 2013;56:181–190.
111. Yamamoto H, Fara AF, Dasgupta P, Kemper C. CD46: The ‘multitasker’ of complement proteins. Int J Biochem Cell Biol. 2013;45:2808–2820.
112. He JQ, Wiesmann C, van Lookeren Campagne M. A role of macrophage complement receptor CRIg in immune clearance and inflammation. Mol Immunol. 2008;45:4041–4047.
113. Zeng Z, Surewaard BG, Wong CH, Geoghegan JA, Jenne CN, Kubes P. CRIg functions as a macrophage pattern recognition receptor to directly bind and capture blood-borne gram-positive bacteria. Cell Host Microbe. 2016;20:99–106.
114. Alcorlo M, Martinez-Barricarte R, Fernandez FJ, et al. Unique structure of iC3b resolved at a resolution of 24 A by 3D-electron microscopy. Proc Natl Acad Sci USA. 2011;108:13236–13240.
115. Bajic G, Yatime L, Sim RB, Vorup-Jensen T, Andersen GR. Structural insight on the recognition of surface-bound opsonins by the integrin I domain of complement receptor 3. Proc Natl Acad Sci USA. 2013;110:16426–16431.
116. Lin Z, Schmidt CQ, Koutsogiannaki S, et al. Complement C3dg-mediated erythrophagocytosis: Implications for paroxysmal nocturnal hemoglobinuria. Blood. 2015;126:891–894.
117. Chen X, Yu Y, Mi LZ, Walz T, Springer TA. Molecular basis for complement recognition by integrin alphaXbeta2. Proc Natl Acad Sci USA. 2012;109:4586–4591.
118. Lachmann PJ, Pangburn MK, Oldroyd RG. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med. 1982;156:205–216.
119. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity. Science. 1996;271:348–350.
120. Bergmann-Leitner ES, Leitner WW, Tsokos GC. Complement 3d: From molecular adjuvant to target of immune escape mechanisms. Clin Immunol. 2006;121:177–185.
121. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol. 2008;6:132–142.
122. Blom AM, Hallstrom T, Riesbeck K. Complement evasion strategies of pathogens-acquisition of inhibitors and beyond. Mol Immunol. 2009;46:2808–2817.
123. Berends ET, Kuipers A, Ravesloot MM, Urbanus RT, Rooijakkers SH. Bacteria under stress by complement and coagulation. FEMS Microbiol Rev. 2014;38:1146–1171.
124. Ram S, Shaughnessy J, DeOliveira RB, Lewis LA, Gulati S, Rice PA. Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae. Immunobiology. 2016;221:1110–1123.
125. Schneider MC, Prosser BE, Caesar JJ, et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009;458:890–893.
126. Seib KL, Scarselli M, Comanducci M, Toneatto D, Masignani V. Neisseria meningitidis factor H-binding protein fHbp: A key virulence factor and vaccine antigen. Expert Rev Vaccines. 2015;14:841–859.
127. Herbert AP, Makou E, Chen ZA, et al. Complement evasion mediated by enhancement of captured factor H: Implications for protection of self-surfaces from complement. J Immunol. 2015;195:4986–4998.
128. Schmidt CQ, Kennedy AT, Tham WH. More than just immune evasion: Hijacking complement by Plasmodium falciparum. Mol Immunol. 2015;67:71–84.
129. Simon N, Lasonder E, Scheuermayer M, et al. Malaria parasites co-opt human factor H to prevent complement-mediated lysis in the mosquito midgut. Cell Host Microbe. 2013;13:29–41.
130. Wu YQ, Qu H, Sfyroera G, et al. Protection of nonself surfaces from complement attack by factor H-binding peptides: Implications for therapeutic medicine. J Immunol. 2011;186:4269–4277.
131. Nilsson PH, Ekdahl KN, Magnusson PU, et al. Autoregulation of thromboinflammation on biomaterial surfaces by a multicomponent therapeutic coating. Biomaterials. 2013;34:985–994.
132. Ojha H, Panwar HS, Gorham RD Jr, Morikis D, Sahu A. Viral regulators of complement activation: Structure, function and evolution. Mol Immunol. 2014;61:89–99.
133. Sfyroera G, Katragadda M, Morikis D, Isaacs SN, Lambris JD. Electrostatic modeling predicts the activities of orthopoxvirus complement control proteins. J Immunol. 2005;174:2143–2151.
134. Kostavasili I, Sahu A, Friedman HM, Eisenberg RJ, Cohen GH, Lambris JD. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus. J Immunol. 1997;158:1763–1771.
135. Chen H, Ricklin D, Hammel M, et al. Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc Natl Acad Sci USA. 2010;107:17621–17626.
136. Sharp JA, Echague CG, Hair PS, et al. Staphylococcus aureus surface protein SdrE binds complement regulator factor H as an immune evasion tactic. PLoS ONE. 2012;7:e38407.
137. Amdahl H, Jongerius I, Meri T, et al. Staphylococcal Ecb protein and host complement regulator factor H enhance functions of each other in bacterial immune evasion. J Immunol. 2013;191:1775–1784.
138. Garcia BL, Ramyar KX, Ricklin D, Lambris JD, Geisbrecht BV. Advances in understanding the structure, function, and mechanism of the SCIN and Efb families of Staphylococcal immune evasion proteins. Adv Exp Med Biol. 2012;946:113–133.
139. Haspel N, Ricklin D, Geisbrecht BV, Kavraki LE, Lambris JD. Electrostatic contributions drive the interaction between Staphylococcus aureus protein Efb-C and its complement target C3d. Protein Sci. 2008;17:1894–1906.
140. Hammel M, Sfyroera G, Ricklin D, Magotti P, Lambris JD, Geisbrecht BV. A structural basis for complement inhibition by Staphylococcus aureus. Nat Immunol. 2007;8:430–437.
141. Ricklin D, Ricklin-Lichtsteiner SK, Markiewski MM, Geisbrecht BV, Lambris JD. Cutting edge: Members of the Staphylococcus aureus extracellular fibrinogen-binding protein family inhibit the interaction of C3d with complement receptor 2. J Immunol. 2008;181:7463–7467.
142. Jongerius I, Puister M, Wu J, Ruyken M, van Strijp JA, Rooijakkers SH. Staphylococcal complement inhibitor modulates phagocyte responses by dimerization of convertases. J Immunol. 2010;184:420–425.
143. Vogel CW, Fritzinger DC. Cobra venom factor: Structure, function, and humanization for therapeutic complement depletion. Toxicon. 2010;56:1198–1222.
144. Myamoto DT, Pidde-Queiroz G, Pedroso A, Goncalves-de-Andrade RM, van den Berg CW, Tambourgi DV. Characterization of the gene encoding component C3 of the complement system from the spider Loxosceles laeta venom glands: Phylogenetic implications. Immunobiology. 2016;221:953–963.
145. Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD. Applying complement therapeutics to rare diseases. Clin Immunol. 2015;161:225–240.
146. S Reis E, Falcao DA, Isaac L. Clinical aspects and molecular basis of primary deficiencies of complement component C3 and its regulatory proteins factor I and factor H. Scand J Immunol. 2006;63:155–168.
147. Okura Y, Yamada M, Takezaki S, et al. Novel compound heterozygous mutations in the C3 gene: Hereditary C3 deficiency. Pediatr Int. 2011;53:e16–19.
148. da Silva KR, Fraga TR, Lucatelli JF, Grumach AS, Isaac L. Skipping of exon 27 in C3 gene compromises TED domain and results in complete human C3 deficiency. Immunobiology. 2016;221:641–649.
149. Ghannam A, Fauquert JL, Thomas C, Kemper C, Drouet C. Human complement C3 deficiency: Th1 induction requires T cell-derived complement C3a and CD46 activation. Mol Immunol. 2014;58:98–107.
150. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci. 2015;282:20143085.
151. Audemard-Verger A, Descloux E, Ponard D, et al. Infections revealing complement deficiency in adults: A French Nationwide Study enrolling 41 patients. Medicine (Baltimore). 2016;95:e3548.
152. Botto M, Fong KY, So AK, et al. Homozygous hereditary C3 deficiency due to a partial gene deletion. Proc Natl Acad Sci USA. 1992;89:4957–4961.
153. Goldberg M, Fremeaux-Bacchi V, Koch P, Fishelson Z, Katz Y. A novel mutation in the C3 gene and recurrent invasive pneumococcal infection: A clue for vaccine development. Mol Immunol. 2011;48:1926–1931.
154. Ghannam A, Pernollet M, Fauquert JL, et al. Human C3 deficiency associated with impairments in dendritic cell differentiation, memory B cells, and regulatory T cells. J Immunol. 2008;181:5158–5166.
155. Tsukamoto H, Horiuchi T, Kokuba H, et al. Molecular analysis of a novel hereditary C3 deficiency with systemic lupus erythematosus. Biochem Biophys Res Commun. 2005;330:298–304.
156. Ulbrich AG, Florido MP, Nudelman V, Reis ES, Baracho GV, Isaac L. Hereditary human complement C3 deficiency owing to reduced levels of C3 mRNA. Scand J Immunol. 2001;53:622–626.
157. Pekkarinen PT, Heikkila N, Kisand K, et al. Dysregulation of adaptive immune responses in complement C3-deficient patients. Eur J Immunol. 2015;45:915–921.
158. Angioi A, Fervenza FC, Sethi S, et al. Diagnosis of complement alternative pathway disorders. Kidney Int. 2016;89:278–288.
159. K Liszewski M, Atkinson JP. Complement regulators in human disease: Lessons from modern genetics. J Intern Med. 2015;277:294–305.
160. Nilsson SC, Sim RB, Lea SM, Fremeaux-Bacchi V, Blom AM. Complement factor I in health and disease. Mol Immunol. 2011;48:1611–1620.
161. Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov. 2015;14:857–877.
162. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: Therapeutic interventions. J Immunol. 2013;190:3839–3847.
163. Qu H, Ricklin D, Bai H, et al. New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology. 2013;218:496–505.
164. Delanghe JR, Speeckaert R, Speeckaert MM. Complement C3 and its polymorphism: Biological and clinical consequences. Pathology. 2014;46:1–10.
165. Bu F, Borsa NG, Jones MB, et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol. 2016;27:1245–1253.
166. Duvvari MR, Paun CC, Buitendijk GH, et al. Analysis of rare variants in the C3 gene in patients with age-related macular degeneration. PLoS ONE. 2014;9:e94165.
167. Iatropoulos P, Noris M, Mele C, et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016;71:131–142.
168. Martinez-Barricarte R, Heurich M, Lopez-Perrote A, et al. The molecular and structural bases for the association of complement C3 mutations with atypical hemolytic uremic syndrome. Mol Immunol. 2015;66:263–273.
169. Saksens NT, Geerlings MJ, Bakker B, et al. Rare genetic variants associated with development of age-related macular degeneration. JAMA Ophthalmol. 2016;134:287–293.
170. Schramm EC, Roumenina LT, Rybkine T, et al. Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome. Blood. 2015;125:2359–2369.
171. Seddon JM, Silver RE, Kwong M, Rosner B. Risk prediction for progression of macular degeneration: 10 common and rare genetic variants, demographic, environmental, and macular covariates. Invest Ophthalmol Vis Sci. 2015;56:2192–2202.
172. Szarvas N, Szilagyi A, Csuka D, et al. Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Mol Immunol. 2016;71:10–22.
173. Zhang T, Lu J, Liang S, et al. Comprehensive analysis of complement genes in patients with atypical hemolytic uremic syndrome. Am J Nephrol. 2016;43:160–169.
174. Harris CL, Heurich M, Rodriguez de Cordoba S, Morgan BP. The complotype: Dictating risk for inflammation and infection. Trends Immunol. 2012;33:513–521.
175. Heurich M, Martinez-Barricarte R, Francis NJ, et al. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA. 2011;108:8761–8766.
176. Fritsche LG, Igl W, Bailey JN, et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nat Genet. 2016;48:134–143.
177. Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in aging and age-related macular degeneration: Hypothesis re-visited. Prog Retin Eye Res. 2010;29:95–112.
178. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8:622–633.
179. Riedl M, Thorner P, Licht C. C3 glomerulopathy. Pediatr Nephrol. 1007;2016. doi:10/s00467-015-3310-4.
180. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554–562.
181. Martinez-Barricarte R, Heurich M, Valdes-Canedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest. 2010;120:3702–3712.
182. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844–1859.
183. Barbu A, Hamad OA, Lind L, Ekdahl KN, Nilsson B. The role of complement factor C3 in lipid metabolism. Mol Immunol. 2015;67:101–107.
184. Lines SW, Richardson VR, Thomas B, Dunn EJ, Wright MJ, Carter AM. Complement and cardiovascular disease—The missing link in haemodialysis patients. Nephron. 2016;132:5–14.
185. Maekawa T, Briones RA, Resuello RR, et al. Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3. J Clin Periodontol. 2016;43:238–249.
186. Morgan BP. The role of complement in neurological and neuropsychiatric diseases. Expert Rev Clin Immunol. 2015;11:1109–1119.
187. Pio R, Corrales L, Lambris JD. The role of complement in tumor growth. Adv Exp Med Biol. 2014;772:229–262.
188. Sacks S, Karegli J, Farrar CA, et al. Targeting complement at the time of transplantation. Adv Exp Med Biol. 2013;735:247–255.
189. Schmudde I, Laumonnier Y, Kohl J. Anaphylatoxins coordinate innate and adaptive immune responses in allergic asthma. Semin Immunol. 2013;25:2–11.
190. Ricklin D, Lambris JD. New milestones ahead in complement-targeted therapy. Semin Immunol. 2016;28:208–222.
191. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2007;25:1265–1275.
192. Ricklin D, Lambris JD. Therapeutic control of complement activation at the level of the central component C3. Immunobiology. 2016;221:740–746.
193. Mastellos DC, Ricklin D, Hajishengallis E, Hajishengallis G, Lambris JD. Complement therapeutics in inflammatory diseases: Promising drug candidates for C3-targeted intervention. Mol Oral Microbiol. 2016;31:3–17.
194. Mastellos DC, Reis ES, Yancopoulou D, Hajishengallis G, Ricklin D, Lambris JD. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. Immunobiology. 2016;221:1046–1057.
195. Katschke KJ Jr, Wu P, Ganesan R, et al. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J Biol Chem. 2012;287:12886–12892.
196. Fridkis-Hareli M, Storek M, Mazsaroff I, et al. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood. 2011;118:4705–4713.
197. Risitano AM, Notaro R, Pascariello C, et al. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood. 2012;119:6307–6316.
198. Holers VM, Rohrer B, Tomlinson S. CR2-mediated targeting of complement inhibitors: Bench-to-bedside using a novel strategy for site-specific complement modulation. Adv Exp Med Biol. 2013;735:137–154.
199. Schmidt CQ, Bai H, Lin Z, et al. Rational engineering of a minimized immune inhibitor with unique triple-targeting properties. J Immunol. 2013;190:5712–5721.
200. Hebecker M, Alba-Dominguez M, Roumenina LT, et al. An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H. J Immunol. 2013;191:912–921.
201. Nichols EM, Barbour TD, Pappworth IY, et al. An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. Kidney Int. 2015;88:1314–1322.
202. Schmidt CQ, Harder MJ, Nichols EM, et al. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients. Immunobiology. 2016;221:503–511.
203. Clark SJ, Schmidt CQ, White AM, Hakobyan S, Morgan BP, Bishop PN. Identification of factor H-like protein 1 as the predominant complement regulator in Bruch’s membrane: Implications for age-related macular degeneration. J Immunol. 2014;193:4962–4970.
204. Ruseva MM, Ramaglia V, Morgan BP, Harris CL. An anticomplement agent that homes to the damaged brain and promotes recovery after traumatic brain injury in mice. Proc Natl Acad Sci USA. 2015;112:14319–14324.
205. Nordmaj MA, Munthe-Fog L, Hein E, Skjoedt MO, Garred P. Genetically engineered fusion of MAP-1 and factor H domains 1-5 generates a potent dual upstream inhibitor of both the lectin and alternative complement pathways. FASEB J. 2015;29:4945–4955.
206. Mastellos DC, Yancopoulou D, Kokkinos P, et al. Compstatin: A C3-targeted complement inhibitor reaching its prime for bedside intervention. Eur J Clin Invest. 2015;45:423–440.
207. Ricklin D, Lambris JD. Compstatin: A complement inhibitor on its way to clinical application. Adv Exp Med Biol. 2008;632:273–292.
208. Sahu A, Kay BK, Lambris JD. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J Immunol. 1996;157:884–891.
209. Sahu A, Morikis D, Lambris JD. Compstatin, a peptide inhibitor of complement, exhibits species-specific binding to complement component C3. Mol Immunol. 2003;39:557–566.
210. Mallik B, Katragadda M, Spruce LA, et al. Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem. 2005;48:274–286.
211. Magotti P, Ricklin D, Qu H, Wu YQ, Kaznessis YN, Lambris JD. Structure-kinetic relationship analysis of the therapeutic complement inhibitor compstatin. J Mol Recognit. 2009;22:495–505.
212. Katragadda M, Magotti P, Sfyroera G, Lambris JD. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006;49:4616–4622.
213. Fiane AE, Videm V, Lambris JD, Geiran OR, Svennevig JL, Mollnes TE. Modulation of fluid-phase complement activation inhibits hyperacute rejection in a porcine-to-human xenograft model. Transplant Proc. 2000;32:899–900.
214. Fiane AE, Mollnes TE, Videm V, et al. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation. 1999;6:52–65.
215. Nilsson B, Larsson R, Hong J, et al. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood. 1998;92:1661–1667.
216. Soulika AM, Holland MC, Sfyroera G, Sahu A, Lambris JD. Compstatin inhibits complement activation by binding to the beta-chain of complement factor 3. Mol Immunol. 2006;43:2023–2029.
217. Janssen BJ, Halff EF, Lambris JD, Gros P. Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem. 2007;282:29241–29247.
218. Qu H, Magotti P, Ricklin D, et al. Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency. Mol Immunol. 2011;48:481–489.
219. Risitano AM, Ricklin D, Huang Y, et al. Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood. 2014;123:2094–2101.
220. Reis ES, DeAngelis RA, Chen H, Resuello RR, Ricklin D, Lambris JD. Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. Immunobiology. 2015;220:476–482.
221. Zhang Y, Shao D, Ricklin D, et al. Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy. Immunobiology. 2015;220:993–998.
222. Silasi-Mansat R, Zhu H, Georgescu C, et al. Complement inhibition decreases early fibrogenic events in the lung of septic baboons. J Cell Mol Med. 2015;19:2549–2563.
223. Silasi-Mansat R, Zhu H, Popescu NI, et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood. 2010;116:1002–1010.
224. Kourtzelis I, Ferreira A, Mitroulis I, et al. Complement inhibition in a xenogeneic model of interactions between human whole blood and porcine endothelium. Horm Metab Res. 2015;47:36–42.
225. Wang J, Wang L, Xiang Y, Ricklin D, Lambris JD, Chen G. Using an in vitro xenoantibody-mediated complement-dependent cytotoxicity model to evaluate the complement inhibitory activity of the peptidic C3 inhibitor Cp40. Clin Immunol. 2016;162:37–44.
226. Abicht J-M, Kourtzelis Ioannis, Reichart B, et al. Complement C3 inhibitor Cp40 attenuates xenoreactions in pig hearts perfused with human blood. Xenotranplantation. 2016. doi:10.1111/xen.12262.
227. Huber-Lang M, Denk S, Lambris J, van Griensven M. Protective Effects of Compstatin in Hemorrhagic Shock. 9th International Conference on Complement Therapeutics, Rhodes, Greece, 2016.
228. Lindorfer MA, Cook EM, Reis ES, et al. Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. Clin Immunol. 2016;171:32–35.
229. Abe T, Hosur KB, Hajishengallis E, et al. Local complement-targeted intervention in periodontitis: Proof-of-concept using a C5a receptor (CD88) antagonist. J Immunol. 2012;189:5442–5448.
230. Hajishengallis G, Hajishengallis E, Kajikawa T, et al. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application. Semin Immunol. 2016;28:285–291.
231. Huang Y, Reis ES, Knerr PJ, van der Donk WA, Ricklin D, Lambris JD. Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin. ChemMedChem. 2014;9:2223–2226.